TrkA-IN-4, a potent, orally active and allosteric 3 h after administration, exhibited potent antinociceptive effects, with an ED50 of 7.836 mg/kg.
[1]. Tang S, et, al. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114901.
















